Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 18, 2017
What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?
NOVARTIS PHARMS CORP has sixty-eight approved drugs.| International Patents: | 1819 |
| US Patents: | 119 |
| Tradenames: | 58 |
| Ingredients: | 49 |
| NDAs: | 68 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
deferasirox | Tablets | 180 mg | JADENU | 4/28/2016 |
travoprost | Ophthalmic Solution | 0.003% | IZBA | 12/30/2015 |
nepafenac | Ophthalmic Suspension | 0.3% | ILEVRO | 12/21/2015 |
deferasirox | Tablets | 180 mg | JADENU | 10/23/2015 |
deferasirox | Tablets | 90 mg and 360 mg | JADENU | 10/19/2015 |
olopatadine hydrochloride | Ophthalmic Solution | 0.7% | PAZEO | 9/10/2015 |
difluprednate | Ophthalmic Emulsion | 0.05% | DUREZOL | 5/1/2014 |
eltrombopag olamine | Tablets | 12.5 mg and 25 mg | PROMACTA | 2/4/2014 |
eltrombopag olamine | Tablets | 50 mg and 75 mg | PROMACTA | 1/7/2014 |
ciprofloxacin and dexamethasone | Otic Suspension | 0.3%/0.1% | CIPRODEX | 7/31/2012 |
moxifloxacin hydrochloride | Ophthalmic Solution | 10.5% | MOXEZA | 2/29/2012 |
argatroban in sodium chloride | Injection | 1 mg/mL, 50 mL vials | ARGATROBAN | 12/16/2011 |
lapatinib ditosylate | Tablets | 250 mg | TYKERB | 3/14/2011 |
olopatadine hydrochloride | Nasal Spray | 0.665 mg/ Spray | PATANASE | 6/29/2009 |
travoprost (preserved) | Ophthalmic Solution | 0.00% | TRAVATAN Z | 2/19/2009 |
olopatadine hydrochloride | Ophthalmic Solution | 0.20% | PATADAY | 9/8/2008 |
argatroban | Injection | 100 mg/mL, 2.5 mL vials | ARGATROBAN | 9/24/2007 |
olopatadine hydrochloride | Ophthalmic Solution | 0.10% | PATANOL | 7/17/2006 |
moxifloxacin hydrochloride | Ophthalmic | 0.50% | VIGAMOX | 12/22/2005 |
ondansetron hydrochloride | Oral Solution | 4 mg/5 mL | ZOFRAN | 12/20/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,825,116 | N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines | ► Subscribe | |||||||||||||
| 8,557,806 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | ► Subscribe | |||||||||||||
| 7,754,733 | Crystalline topotecan hydrochloride product and process for making the same | ► Subscribe | |||||||||||||
| 6,486,138 | Ophthalmic compositions containing galactomannan polymers and borate | ► Subscribe | |||||||||||||
| 8,334,296 | 2,4-pyrimidinediamine compounds and their uses | ► Subscribe | |||||||||||||
| 9,346,765 | 2,4-pyrimidinediamine compounds and their uses | ► Subscribe | |||||||||||||
| 7,858,626 | Pyrimidineamines as angiogenesis modulators | ► Subscribe | |||||||||||||
| 9,499,493 | 2,4-pyrimidinediamine compounds and their uses | ► Subscribe | |||||||||||||
| 7,812,029 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | ► Subscribe | |||||||||||||
| 7,557,210 | 2,4-pyrimidinediamine compounds and their uses | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 497495 | ► Subscribe | |||||||||||||
| Portugal | 1660458 | ► Subscribe | |||||||||||||
| Brazil | PI0722384 | ► Subscribe | |||||||||||||
| Colombia | 6341561 | ► Subscribe | |||||||||||||
| Spain | 2550942 | ► Subscribe | |||||||||||||
| Denmark | 0999825 | ► Subscribe | |||||||||||||
| Mexico | PA03001832 | ► Subscribe | |||||||||||||
| China | 1200926 | ► Subscribe | |||||||||||||
| Taiwan | I544927 | ► Subscribe | |||||||||||||
| Portugal | 2298768 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014039,C1761528 | Lithuania | ► Subscribe | PRODUCT NAME: TRAMETINIBAS; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630 | ||||||||||||
| C/GB03/004 | United Kingdom | ► Subscribe | PRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309 | ||||||||||||
| C/GB12/058 | United Kingdom | ► Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 | ||||||||||||
| 2015 00026 | Denmark | ► Subscribe | PRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753, C(2014)8916 20141121 | ||||||||||||
| C0049 | France | ► Subscribe | PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828 | ||||||||||||
| 2004012 | Lithuania | ► Subscribe | PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS) | ||||||||||||
| 00671 | Netherlands | ► Subscribe | PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128 | ||||||||||||
| 2013000085 | Germany | ► Subscribe | PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503 | ||||||||||||
| 1343782/01 | Switzerland | ► Subscribe | FORMER OWNER: GLAXOSMITHKLINE LLC, US | ||||||||||||
| 90022-1 | Sweden | ► Subscribe | PRODUCT NAME: PASIREOTID; REG. NO/DATE: EU/1/12/753/001 20120424 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,931 others who get our Drug Patent Expiration Alerts:
